8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                              -------------------

                                    FORM 8-K
                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                              -------------------

       Date of Report (Date of earliest event reported): December 7, 2000

                         AmeriSource Health Corporation
             (Exact name of Registrant as specified in its charter)

             Delaware                     33-27835-01           23-2546940
  (State or Other Jurisdiction     (Commission File Number)  (I.R.S. Employer
of Incorporation or Organization)                            Identification No.)

                              -------------------

                                  P.O. Box 959
                        Valley Forge, Pennsylvania 19482
                   (Address of Principal Executive Offices)

                                (610) 727-7000
             (Registrant's telephone number, including area code)

                               -------------------

                                 Not Applicable
          (Former name or former address, if changed since last report)

                              -------------------


Item 5. Other Events.
        ------------

     On December 7, 2000, AmeriSource Health Corporation announced that it has
offered and priced a new issue of $250 million of Convertible Subordinated Notes
due 2007 in a private placement. A copy of the press release is filed as Exhibit
99.1 to this Report.

Item 7. Financial Statements and Exhibits
        ---------------------------------

          (c)  Exhibits.

               99.1 Press Release dated December 7, 2000



     Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

                                  AMERISOURCE HEALTH CORPORATION

December 7, 2000                         By:  /s/ George L. James III
                                  ----------------------------------------------
                                     George L. James III
                                     Vice President and Chief Financial Officer



                                  EXHIBIT INDEX

Number     Exhibit

99.1       Press Release dated December 7, 2000

EX-99.1

AmeriSource Prices $250 Million Convertible Subordinated Note Offering

     VALLEY FORGE, PENNSYLVANIA - December 7, 2000 - AmeriSource Health
Corporation today announced that it has offered and priced a new issue of $250
million of Convertible Subordinated Notes due 2007. The notes will have an
annual interest rate of 5%, payable semi-annually, and will be convertible into
Class A Common Stock of the Company at approximately $52.97 per share. The
Company may also issue up to an additional $50 million of the notes pursuant to
an option that has been granted to the initial purchasers. The Company intends
to use the net proceeds from the sale of the notes to repay existing borrowings,
and for working capital and other general corporate purposes. The notes will
provide longer term, fixed rate debt at a lower cost than existing debt. The
notes are being issued in a private placement and are expected to be resold by
the initial purchasers to qualified institutional buyers under Rule 144A of the
Securities Act of 1933.

     The notes and the common stock issuable upon conversion of the notes have
not been registered under the Securities Act and may not be offered or sold in
the United States absent registration or an applicable exemption from the
registration requirements. This does not constitute an offer to sell or the
solicitation of an offer to buy any security in any jurisdiction in which such
offer or sale would be unlawful.

                                    # # # #

     Certain information contained in this press release includes
forward-looking statements (as defined in Section 27A of the Securities Act and
Section 21E of the Exchange Act) that reflect the Company's current views with
respect to future events and financial performance. Certain factors such as
competitive pressures, success of restructuring or systems initiatives, market
interest rates, regulatory changes, continued industry consolidation, changes in
customer mix, changes in pharmaceutical manufacturers' pricing and distribution
policies, changes in U.S. government policies, customer insolvencies, the loss
of one or more key customer or supplier relationships and other matters
contained in the Company's 10-K for fiscal year 1999 and other public documents
could cause actual results to differ materially from those in the forward-
looking statements. The Company assumes no obligation to update the matters
discussed in this press release.